Evidence map›Paper›PMID 38136364›Full record

ArticleCancers2023

In Vitro Organoid-Based Assays Reveal SMAD4 Tumor-Suppressive Mechanisms for Serrated Colorectal Cancer Invasion.

Kevin Tong, Manisha Bandari, Jillian N Carrick, Anastasia Zenkevich, Om A Kothari, Eman Shamshad, Katarina Stefanik, Katherine S Haro, Ansu O Perekatt, Michael P Verzi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kevin TongDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0009-0002-6371-4644
Manisha BandariDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.ORCID 0009-0008-0329-6050
Jillian N CarrickDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Anastasia ZenkevichHackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ 07110, USA.
Om A KothariDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Eman ShamshadDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Katarina StefanikDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Katherine S HaroDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Ansu O PerekattDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Michael P VerziDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Rutgers, The State University of New Jersey · USHackensack Meridian Health · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI EDMUND C. LATTIME · 1997 to 2026
$94.5M
Transcriptional Mechanisms of Tumor SuppressionR01CA190558 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI MICHAEL P. VERZI · 2015 to 2026
$3.6M
Elucidating the Role of SMAD4 in Colorectal CancerR00CA245123 · NCI · HACKENSACK UNIVERSITY MEDICAL CENTER · PI TONG, KEVIN · 2022 to 2024
$747k
Elucidating the Role of SMAD4 in Colorectal CancerK99CA245123 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI TONG, KEVIN · 2020 to 2021
$241k
SMAD4 in Serrated TumorigenesisF32CA235829 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI TONG, KEVIN · 2019 to 2020
$89k
NCI NIH HHS 1F32CA235829NCI NIH HHS 4R00CA245123NCI NIH HHS 5K99CA245123NCI NIH HHS F32 CA235829NCI NIH HHS K99 CA245123NCI NIH HHS P30 CA072720NCI NIH HHS P30CA072720NCI NIH HHS R00 CA245123NCI NIH HHS R01 CA190558NCI NIH HHS R01CA190558NIH HHS INSIGHT
6 · The paper itself

Abstract

Colon cancer is the third most prominent cancer and second leading cause of cancer-related deaths in the United States. Up to 20% of colon cancers follow the serrated tumor pathway driven by mutations in the MAPK pathway. Loss of SMAD4 function occurs in the majority of late-stage colon cancers and is associated with aggressive cancer progression. Therefore, it is important to develop technology to accurately model and better understand the genetic mechanisms behind cancer invasion. Organoids derived from tumors found in the

Indexed as

colon cancerinvasionorganoidsSMAD4

Identifiers

PMID38136364
PMCPMC10742020
OpenAlexW4389678239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.